Tirzepatide (CAS No. 2023788-19-2)

Dual GIP / GLP-1 Receptor Agonist API rau Hom 2 Mob ntshav qab zib thiab rog

Peb muabtshuaj-qibTirzepatideAPItsim los rau cov qauv zoo rau kev tsim cov tshuaj txhaj tshuaj. Tirzepatide yog dualGIP thiab GLP-1 receptor agonistuas ua haujlwm los ntawm ob txoj hauv kev ntxiv incretin los txhawb kev tswj ntshav qabzib thiab tswj lub cev hnyav. Ua tsaug rau nws cov txheej txheem dual thiab ib zaug - noj txhua lub limtiam profile, nws tau dhau los ua ib qho tseem ceeb peptide active ingredient hauv kev kho mob.Hom 2 mob ntshav qab zib mellitus (T2DM)thiabtswj qhov hnyav hnyav.

Raws li tus kws tshaj lij peptide API tus neeg muag khoom, peb muabsiab -purity Tirzepatidenrog kev tswj hwm nruj, txhim khu kev qha batch sib xws, thiab hloov tau lub peev xwm rau cov tuam txhab tshuaj, cov tsim qauv tsim, thiab cov chaw tshawb fawb.

Cov ntaub ntawv khoom

Product Overview

Tirzepatide yog ib qho tshiab peptide API tsim los qhib ob qho tib siGIPthiabGLP-1 receptors. Los ntawm kev tsom mus rau ob txoj kev incretin tib lub sijhawm, nws pab tswj cov piam thaj metabolism, insulin secretion, glucagon tso tawm, plab hnyuv plab, qab los noj mov, thiab lub cev hnyav.

Piv nrog rau ib leeg - txoj kev kho incretin, Tirzepatide muaj cov txheej txheem dav dav ntawm kev ua haujlwm thiab tau txais kev txaus siab rau txoj kev loj hlob ntawm kev kho mob rau cov kab mob metabolic. Nws ib nrab ntev -lub neej kuj txhawb nqaib zaug - kev tswj hwm txhua lub lim tiam, ua kom nws zoo haum rau cov ntawv txhaj tshuaj.

Daim ntawv thov

1. Hom 2 mob ntshav qab zib mellitus

Tirzepatide tau siv dav hauv kev txhim kho kev kho mob rau cov neeg mob uas muaj ntshav qab zib hom 2, tshwj xeeb yog qhov yuav tsum tau ua kom muaj kev tswj hwm glycemic. Nws tuaj yeem siv los ua kev kho mob monotherapy lossis ua ke nrog lwm cov tshuaj tiv thaiv kab mob xws li metformin, SGLT2 inhibitors, lossis insulin-raws li kev tswj hwm, nyob ntawm kev tsim cov tswv yim thiab kev siv tshuaj kho mob.

Ntxiv nrog rau kev tswj ntshav qabzib, Tirzepatide kuj tau txais kev saib xyuas rau nws cov txiaj ntsig muaj peev xwm hauv kev tswj hwm cardiometabolic, suav nrog kev txhawb nqa rau kev txo qhov hnyav thiab txhim kho cov teeb meem cuam tshuam txog metabolic.

2. Kev tswj qhov hnyav

Tirzepatide kuj yog ib qho tseem ceeb active ingredient nyob rau hauv txoj kev loj hlob ntawm cov kev kho mob rau cov rog rog thiab rog rog cov neeg mob uas hnyav -txog comorbidities. Los ntawm kev sib koom ua ke ntawm GIP thiab GLP-1 receptor activation, nws pab txo qis qab los noj mov thiab txhawb nqa lub cev hnyav, ua rau nws muaj txiaj ntsig peptide API rau cov qauv tswj kev hnyav hnyav.

Dosage Form Development

Tirzepatide feem ntau yog siv rau hauv kev loj hlob ntawmib zaug - cov tshuaj txhaj tshuaj txhua lub lim tiamrau kev tswj hwm subcutaneous. Nws yog qhov tsim nyog rau cov ntawv thov xws li ua ntej - cov cwj mem puv thiab lwm lub tshuab peptide txhaj tshuaj. Cov kev xaiv muaj zog sib txawv tuaj yeem tsim raws li kev tsim thiab kev ua lag luam.

Quality Assurance

Kev ua tau zoo yog qhov tseem ceeb rau peptide APIs, tshwj xeeb tshaj yog rau kev txhaj tshuaj. Peb Tirzepatide yog tsim nyob rau hauv cov txheej txheem nruj tswj kom paub meej purity, tus kheej, ruaj khov, thiab batch-rau-batch sib xws.

Raw Materials thiab Manufacturing

Peb siv ua tib zoo xaiv cov khoom pib thiab qib siab peptide synthesis technology los txhawb cov khoom zoo. Kev tsim khoom yog nqa tawm hauv cov chaw tswj kev sivsolid-phase peptide synthesis (SPPS), ua raws li kev lim dej thiab lyophilization raws li cov qauv kev ua haujlwm nruj.

Cov txheej txheem tseem ceeb, suav nrog kev sib txuas ua haujlwm, kev tswj tsis huv, kev ua kom huv huv, thiab qhov kawg kom qhuav, raug saib xyuas zoo thoob plaws hauv kev tsim khoom kom ntseeg tau zoo ib yam.

Kev xeem thiab tso tawm cov qauv

Txhua batch raug soj ntsuam raws li cov qauv zoo thiab cov neeg siv khoom xav tau. Cov khoom kuaj muaj xws li:

HPLC purity thiab lwm yam tshuaj

Peptide kev lees paub tus kheej

Cov dej noo

Residual solvent tsom xam

Hnyav hlau kuaj

Kev kuaj Endotoxin

Microbial txwv

Lwm yam tshuaj txhaj tshuaj - qib tswj cov khoom raws li kev thov

Txhawb cov ntaub ntawv xws liCOA, analytical data, thiab technical documentationmuaj rau cov neeg siv khoom tsim nyog.

Kev nyab xeeb thiab tuav

Tirzepatideyog npaj raukev tsim tshuaj, kev tsim kho, thiab kev tshawb fawb siv los ntawm cov kws tshaj lij uas tsim nyog nkaus xwb. Cov txheej txheem tuav tsim nyog yuav tsum tau ua raws li kev khaws cia, kev ua, thiab kev tsim.

Vim tias qhov no yog cov khoom muaj peptide muaj zog heev, cov tuam txhab lag luam yuav tsum ntsuas kev sib raug zoo ntawm kev tsim khoom, kev tsim tshuaj, kev xaiv cov khoom noj khoom haus, kev hloov pauv tus cwj pwm, thiab kev ruaj ntseg ntev - lub sij hawm tsim khoom.

Supply Capacity thiab Service

Peb muab Tirzepatide API rau ntau yam kev txhim kho thiab kev tsim khoom, los ntawmR&D kom muaj nuj nqis rau kev lag luam loj dua - nplai xaj. Peb ua haujlwm nrog cov tuam txhab tshuaj, cov tuam txhab cog lus, tsim cov qauv tsim, thiab cov koom haum tshawb fawb thoob ntiaj teb.

Peb qhov kev pab txhawb nqa suav nrog:

Kev ruaj ntseg API khoom

Kev txiav txim kom muaj nuj nqis

Kev them nyiaj yug cov ntaub ntawv

COA thiab zoo - cov ntaub ntawv ntsig txog

Ntim cov kev xaiv rau cov theem sib txawv

Kev sib txuas lus rau kev tsim thiab kev cia khoom

Tiv tauj peb

Yog tias koj tab tom nrhiav kev txhim khu kev qhaTirzepatideAPI tus neeg muag khoom, thov hu rau peb kom paub meej cov khoom, cov ntaub ntawv kev, hais lus, thiab muab kev txhawb nqa.

Email:sales@huarongpharma.com
Xov tooj / WhatsApp: +86 13751168070

Peb tos ntsoov yuav ua haujlwm nrog cov neeg koom tes thoob ntiaj teb ntawm kev ua haujlwm siab -peptide API khoom thiab kev koom tes ntev -.

FAQ

1. Tirzepatide siv rau dab tsi?

Tirzepatide yog dual GIP / GLP-1 receptor agonist siv los ua cov tshuaj muaj txiaj ntsig hauv kev txhim kho kev kho mob.mob ntshav qab zib hom 2thiabtswj qhov hnyav hnyav.

2. Dab tsi yog qhov zoo ntawm Tirzepatide?

Nws cov txiaj ntsig tseem ceeb suav nrog adual incretin mechanism, kev txhawb nqa rauglycemic tswj thiab tswj qhov hnyav, thiab antev ib nrab -lub neejuas tso cai rau ib zaug - kev tswj hwm txhua lub lim tiam hauv cov tshuaj txhaj tshuaj.

3. Daim ntawv npaum li cas Tirzepatide tuaj yeem siv rau hauv?

Tirzepatide feem ntau yog siv rau hauvsubcutaneous txhaj tshuaj formulations, suav nrog ua ntej- cov cwj mem puv thiab lwm yam ib zaug - cov khoom txhaj tshuaj txhua lub lim tiam.

4. Cov ntaub ntawv zoo dab tsi koj tuaj yeem muab tau?

Rau cov neeg siv khoom tsim nyog, peb tuaj yeem muab cov ntaub ntawv xws liCOA, purity data, analytical reports, and other technical informationraws li qhov xav tau ntawm qhov project.

5. Dab tsi txiav txim kom muaj nuj nqis koj txhawb?

Peb txhawb cov khoom lag luam hloov pauv xws lime R & D cov qauv rau kev txiav txim loj loj, nyob ntawm cov neeg siv khoom xav tau thiab qhov project theem.